Next Article in Journal
Cytotoxic Aβ Protofilaments Are Generated in the Process of Aβ Fibril Disaggregation
Previous Article in Journal
Deficiency of T-Cell Intracellular Antigen 1 in Murine Embryonic Fibroblasts Is Associated with Changes in Mitochondrial Morphology and Respiration
Previous Article in Special Issue
An RNA-Seq-Based Framework for Characterizing Canine Prostate Cancer and Prioritizing Clinically Relevant Biomarker Candidate Genes
Review

CRISPR Screen Contributes to Novel Target Discovery in Prostate Cancer

1
Department of Urology, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan
2
Division of Urology, Department of Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
3
Translational Research Program, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan
*
Authors to whom correspondence should be addressed.
Academic Editors: Gian Maria Busetto, Alessandro Sciarra, Angelo Porreca, Matteo Ferro and Ettore De Berardinis
Int. J. Mol. Sci. 2021, 22(23), 12777; https://doi.org/10.3390/ijms222312777
Received: 30 October 2021 / Revised: 25 November 2021 / Accepted: 25 November 2021 / Published: 26 November 2021
(This article belongs to the Special Issue Advances in Molecular Research on Prostate Cancer)
Prostate cancer (PCa) is one of the common malignancies in male adults. Recent advances in omics technology, especially in next-generation sequencing, have increased the opportunity to identify genes that correlate with cancer diseases, including PCa. In addition, a genetic screen based on CRISPR/Cas9 technology has elucidated the mechanisms of cancer progression and drug resistance, which in turn has enabled the discovery of new targets as potential genes for new therapeutic targets. In the era of precision medicine, such knowledge is crucial for clinicians in their decision-making regarding patient treatment. In this review, we focus on how CRISPR screen for PCa performed to date has contributed to the identification of biologically critical and clinically relevant target genes. View Full-Text
Keywords: prostate cancer; CRISPR screen; CRISPR/Cas9 prostate cancer; CRISPR screen; CRISPR/Cas9
Show Figures

Figure 1

MDPI and ACS Style

Tsujino, T.; Komura, K.; Inamoto, T.; Azuma, H. CRISPR Screen Contributes to Novel Target Discovery in Prostate Cancer. Int. J. Mol. Sci. 2021, 22, 12777. https://doi.org/10.3390/ijms222312777

AMA Style

Tsujino T, Komura K, Inamoto T, Azuma H. CRISPR Screen Contributes to Novel Target Discovery in Prostate Cancer. International Journal of Molecular Sciences. 2021; 22(23):12777. https://doi.org/10.3390/ijms222312777

Chicago/Turabian Style

Tsujino, Takuya, Kazumasa Komura, Teruo Inamoto, and Haruhito Azuma. 2021. "CRISPR Screen Contributes to Novel Target Discovery in Prostate Cancer" International Journal of Molecular Sciences 22, no. 23: 12777. https://doi.org/10.3390/ijms222312777

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop